Signed in as:
filler@godaddy.com
Signed in as:
filler@godaddy.com
“Across three studies evaluating this novel technology, operators achieved first-pass full reperfusion rates ranging from 60% to 69%—a substantial improvement over the 40% to 42% rates typically observed with current-generation devices,” said Marc Ribo, M.D. Professor of Neurology at Vall d’Hebron University Hospital.
BMJ Journals - SNIS 2022
May 6, 2025
May 6, 2025 | Source: GlobeNewswire
December 11, 2024
December 11, 2024 | Source: GlobeNewswire
April 4, 2024
April 4, 2024 | Source: GlobeNewsWire
May 31, 2023
May 31, 2023
May 24, 2023
May 24, 2023 | ESOC 2023
September 13, 2022
September 13, 2022 | Source: Steven Loeb, vatornews
September 13, 2022
September 13, 2022 | Source: Endovascular Today
July 28, 2022
July 28, 2022 | Source: BMJ Journals
June 28, 2021
June 28, 2021 | Source: Andrea Park, FierceBiotech
June 23, 2021
June 23, 2021 | Source: GlobeNewswire
The RapidPulse™ System is not yet cleared for marketing by the US FDA. It is not available for commercial sale.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.